Drug Repurposing in Rett and Rett-like Syndromes: a Promising Yet Underrated Opportunity?

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Aug 13

PMID 39135718

Authors

Claudia Fuchs

Peter A C t Hoen

Annelieke R Muller

Friederike Ehrhart

Clara D M van Karnebeek

Affiliations

Soon will be listed here.

Abstract

Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). The severity and complexity of symptoms associated with these disorders, including cognitive impairment, motor dysfunction, seizures and other neurological features significantly affect the quality of life of patients and families. Despite ongoing research efforts to identify potential therapeutic targets and develop novel treatments, current therapeutic options remain limited. Here the potential of drug repurposing (DR) as a promising avenue for addressing the unmet medical needs of individuals with RTT and related disorders is explored. Leveraging existing drugs for new therapeutic purposes, DR presents an attractive strategy, particularly suited for neurological disorders given the complexities of the central nervous system (CNS) and the challenges in blood-brain barrier penetration. The current landscape of DR efforts in these syndromes is thoroughly examined, with partiuclar focus on shared molecular pathways and potential common drug targets across these conditions.

References

Zhu Z, Li Y, Xu J, Xue H, Feng X, Zhu Y . CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling. Cell Rep. 2023; 42(10):113202. DOI: 10.1016/j.celrep.2023.113202. View

Dichtel L, Nyer M, Dording C, Fisher L, Cusin C, Shapero B . Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study. J Clin Psychiatry. 2020; 81(4). PMC: 7738196. DOI: 10.4088/JCP.19m12887. View

Persico A, Ricciardello A, Cucinotta F . The psychopharmacology of autism spectrum disorder and Rett syndrome. Handb Clin Neurol. 2019; 165:391-414. DOI: 10.1016/B978-0-444-64012-3.00024-1. View

Vossler D . Ganaxolone: A New Treatment for CDKL5 Deficiency Disorder. Epilepsy Curr. 2022; 22(6):348-350. PMC: 9661611. DOI: 10.1177/15357597221125238. View

Jonker A, OConnor D, Cavaller-Bellaubi M, Fetro C, Gogou M, t Hoen P . Drug repurposing for rare: progress and opportunities for the rare disease community. Front Med (Lausanne). 2024; 11:1352803. PMC: 10828010. DOI: 10.3389/fmed.2024.1352803. View

Olson H, Demarest S, Pestana-Knight E, Swanson L, Iqbal S, Lal D . Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. Pediatr Neurol. 2019; 97:18-25. PMC: 7120929. DOI: 10.1016/j.pediatrneurol.2019.02.015. View

Fehr S, Wong K, Chin R, Williams S, de Klerk N, Forbes D . Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology. 2016; 87(21):2206-2213. DOI: 10.1212/WNL.0000000000003352. View

Goetz C, Damier P, Hicking C, Laska E, Muller T, Olanow C . Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2006; 22(2):179-86. DOI: 10.1002/mds.21226. View

Bray N . Neurodevelopmental disorders: righting Rett syndrome with IGF1. Nat Rev Drug Discov. 2014; 13(9):653. DOI: 10.1038/nrd4417. View

10.

Ben-Ari Y, Cherubini E . The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis. Cells. 2022; 11(3). PMC: 8834580. DOI: 10.3390/cells11030396. View

11.

Rynn M, Wagner K, Donnelly C, Ambrosini P, Wohlberg C, Landau P . Long-term sertraline treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006; 16(1-2):103-16. DOI: 10.1089/cap.2006.16.103. View

12.

Braun S, Kottwitz D, Nuber U . Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome. Hum Mol Genet. 2011; 21(8):1673-80. DOI: 10.1093/hmg/ddr602. View

13.

Fung L, Libove R, Phillips J, Haddad F, Hardan A . Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. J Autism Dev Disord. 2014; 44(11):2971-7. PMC: 4194260. DOI: 10.1007/s10803-014-2144-4. View

14.

Li W . Excitation and Inhibition Imbalance in Rett Syndrome. Front Neurosci. 2022; 16:825063. PMC: 8894599. DOI: 10.3389/fnins.2022.825063. View

15.

Vogelgesang S, Niebert S, Renner U, Mobius W, Hulsmann S, Manzke T . Analysis of the Serotonergic System in a Mouse Model of Rett Syndrome Reveals Unusual Upregulation of Serotonin Receptor 5b. Front Mol Neurosci. 2017; 10:61. PMC: 5340760. DOI: 10.3389/fnmol.2017.00061. View

16.

Ma Z, Zhang R, Rui W, Wang Z, Feng X . Quercetin alleviates chronic unpredictable mild stress-induced depressive-like behaviors by promoting adult hippocampal neurogenesis via FoxG1/CREB/ BDNF signaling pathway. Behav Brain Res. 2021; 406:113245. DOI: 10.1016/j.bbr.2021.113245. View

17.

Cook E, Wagner K, March J, Biederman J, Landau P, Wolkow R . Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2001; 40(10):1175-81. DOI: 10.1097/00004583-200110000-00011. View

18.

Rasmusson A, Marx C, Jain S, Farfel G, Tsai J, Sun X . A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology (Berl). 2017; 234(15):2245-2257. DOI: 10.1007/s00213-017-4649-y. View

19.

Devinsky O, King L, Schwartz D, Conway E, Price D . Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021; 62(7):e98-e102. PMC: 8360137. DOI: 10.1111/epi.16923. View

20.

De Filippis B, Ricceri L, Fuso A, Laviola G . Neonatal exposure to low dose corticosterone persistently modulates hippocampal mineralocorticoid receptor expression and improves locomotor/exploratory behaviour in a mouse model of Rett syndrome. Neuropharmacology. 2012; 68:174-83. DOI: 10.1016/j.neuropharm.2012.05.048. View